loading
Schlusskurs vom Vortag:
$3.89
Offen:
$3.88
24-Stunden-Volumen:
970.87K
Relative Volume:
0.96
Marktkapitalisierung:
$347.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.03M
KGV:
-7.1429
EPS:
-0.56
Netto-Cashflow:
$-23.97M
1W Leistung:
+7.24%
1M Leistung:
+5.82%
6M Leistung:
-25.23%
1J Leistung:
+119.78%
1-Tages-Spanne:
Value
$3.7101
$4.00
1-Wochen-Bereich:
Value
$3.7101
$4.3763
52-Wochen-Spanne:
Value
$1.75
$10.00

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Name
Firmenname
Corvus Pharmaceuticals Inc
Name
Telefon
(650) 900-4520
Name
Adresse
863 MITTEN ROAD, BURLINGAME, CA
Name
Mitarbeiter
31
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-25
Name
Neueste SEC-Einreichungen
Name
CRVS's Discussions on Twitter

Vergleichen Sie CRVS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CRVS
Corvus Pharmaceuticals Inc
4.00 347.02M 0 -27.03M -23.97M -0.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.20 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
525.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.09 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
551.22 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.07 28.51B 3.81B -644.79M -669.77M -6.24

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-02 Eingeleitet H.C. Wainwright Buy
2023-08-18 Eingeleitet Oppenheimer Outperform
2021-12-01 Fortgesetzt Jefferies Buy
2021-05-27 Eingeleitet Cantor Fitzgerald Overweight
2021-02-10 Herabstufung Mizuho Buy → Neutral
2019-09-12 Eingeleitet Mizuho Buy
2019-05-29 Eingeleitet ROTH Capital Buy
2017-08-24 Hochstufung Credit Suisse Underperform → Neutral
2017-05-01 Herabstufung Credit Suisse Neutral → Underperform
2016-04-18 Eingeleitet Credit Suisse Outperform
2016-04-18 Eingeleitet Guggenheim Buy
Alle ansehen

Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten

pulisher
Jun 18, 2025

Financial Metrics Exploration: Understanding Corvus Pharmaceuticals Inc (CRVS) Through Ratios - DWinneX

Jun 18, 2025
pulisher
Jun 13, 2025

Corvus Pharmaceuticals: Multiple Opportunities, But Plenty Of Risk - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Corvus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 11, 2025

Breakthrough Systemic Sclerosis Treatment Shows Promise in Top EULAR Study | CRVS Stock News - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress - TradingView

Jun 11, 2025
pulisher
Jun 10, 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jun 10, 2025
pulisher
Jun 04, 2025

Corvus reports promising interim data on atopic dermatitis drug By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Reports 'Clinically Meaningful' Itch Reduction in Latest Phase 1 Atopic Dermatitis Drug Trial Results - MarketScreener

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus reports promising interim data on atopic dermatitis drug - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals (CRVS) Reports Promising Results for Atopic Dermatitis Treatment | CRVS Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data From Cohort 3 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data from Cohort 3 - GlobeNewswire

Jun 04, 2025
pulisher
May 28, 2025

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times

May 28, 2025
pulisher
May 20, 2025

Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN

May 20, 2025
pulisher
May 20, 2025

CRVS: Mizuho Adjusts Price Target for Corvus Pharma | CRVS Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positiv - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positive Drug Data | CRVS Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating By Investing.com - Investing.com India

May 20, 2025
pulisher
May 20, 2025

Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating - marketscreener.com

May 20, 2025
pulisher
May 13, 2025

Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by StockNews.com to Hold Rating - Defense World

May 13, 2025
pulisher
May 12, 2025

Corvus Pharmaceuticals (CRVS) Sees Increased Investor Interest A - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Corvus Pharmaceuticals (CRVS) Sees Notable Increase in Borrow Ra - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Spotlight On Top Penny Stocks For May 2025 - simplywall.st

May 12, 2025
pulisher
May 12, 2025

Corvus Pharmaceuticals’ (CRVS) Outperform Rating Reiterated at Oppenheimer - Defense World

May 12, 2025
pulisher
May 10, 2025

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks

May 09, 2025
pulisher
May 09, 2025

CRVS: Oppenheimer Raises Price Target for Corvus Pharma | CRVS S - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 09, 2025
pulisher
May 09, 2025

CRVS: Oppenheimer Raises Price Target for Corvus Pharma | CRVS Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased - Asianet Newsable

May 09, 2025
pulisher
May 09, 2025

Why Is Corvus Pharmaceuticals Stock Soaring On Friday? - Benzinga

May 09, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals shares surge on positive trial results By Investing.com - Investing.com Nigeria

May 09, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals shares surge on positive trial results - Investing.com

May 09, 2025
pulisher
May 09, 2025

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $17 From $15, Maintains Outperform Rating - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Is Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo

May 09, 2025
pulisher
May 09, 2025

Corvus: Q1 Earnings Snapshot - New Haven Register

May 09, 2025
pulisher
May 09, 2025

Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket - Benzinga

May 09, 2025
pulisher
May 09, 2025

Corvus reports positive phase 1 trial results for atopic dermatitis drug - Investing.com

May 09, 2025
pulisher
May 09, 2025

Corvus Pharma Reports 'Favorable' Interim Phase 1 Results in Atopic Dermatitis Trial; Shares Surge Premarket - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals Inc (CRVS) Q1 2025 Earnings Call Highlights: A Turnaround with Promising ... By GuruFocus - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

Corvus Pharmaceuticals Reports Promising Q1 2025 Results - TipRanks

May 09, 2025
pulisher
May 09, 2025

10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey

May 09, 2025
pulisher
May 08, 2025

Corvus Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:CRVS) - Seeking Alpha

May 08, 2025
pulisher
May 08, 2025

Earnings call transcript: Corvus Pharmaceuticals Q1 2025 sees stock surge despite EPS miss - Investing.com India

May 08, 2025
pulisher
May 08, 2025

Corvus Pharmaceuticals Reports Positive Phase 1 Trial Results - TipRanks

May 08, 2025
pulisher
May 08, 2025

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times

May 08, 2025
pulisher
May 08, 2025

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of - GlobeNewswire

May 08, 2025

Finanzdaten der Corvus Pharmaceuticals Inc-Aktie (CRVS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Corvus Pharmaceuticals Inc-Aktie (CRVS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
MILLER RICHARD A MD
President and CEO
May 07 '25
Option Exercise
3.50
559,073
1,956,756
1,136,707
$20.66
price up icon 0.78%
$36.03
price up icon 0.45%
$21.28
price up icon 3.30%
$100.64
price up icon 1.16%
$106.47
price down icon 0.23%
biotechnology ONC
$242.07
price up icon 0.36%
Kapitalisierung:     |  Volumen (24h):